CAS 110347-85-8
:Selfotel
Description:
Selfotel, with the CAS number 110347-85-8, is a chemical compound that belongs to the class of compounds known as neuroprotective agents. It is primarily recognized for its potential therapeutic applications in the treatment of neurological conditions, particularly in the context of ischemic brain injury. Selfotel acts as an antagonist at the N-methyl-D-aspartate (NMDA) receptor, which plays a crucial role in excitatory neurotransmission and is implicated in neurodegenerative processes. By modulating NMDA receptor activity, Selfotel may help to reduce excitotoxicity, a condition where excessive stimulation by neurotransmitters leads to neuronal damage and death. The compound has been studied for its effects on cognitive function and neuroprotection, although its clinical use has been limited. In terms of physical properties, Selfotel is typically characterized by its solubility in organic solvents and its stability under specific conditions. Overall, Selfotel represents a significant area of research in neuropharmacology, with ongoing investigations into its efficacy and safety profile.
Formula:C7H14NO5P
InChI:InChI=1/C7H14NO5P/c9-7(10)6-3-5(1-2-8-6)4-14(11,12)13/h5-6,8H,1-4H2,(H,9,10)(H2,11,12,13)/t5-,6+/s2
InChI key:InChIKey=LPMRCCNDNGONCD-MZQZIECVNA-N
SMILES:C(P(=O)(O)O)[C@H]1C[C@@H](C(O)=O)NCC1
Synonyms:- (2S,4R)-4-(phosphonomethyl)piperidine-2-carboxylic acid
- 2-Piperidinecarboxylic acid, 4-(phosphonomethyl)-, (2R,4S)-rel-
- 2-Piperidinecarboxylic acid, 4-(phosphonomethyl)-, cis-
- Cgs 19755
- Cpdd 0027
- Selfotel [USAN:INN]
- cis-4-(Phosphonomethyl)pipecolic acid
- cis-4-[Phosphonomethyl]-2-piperidinecarboxylic acid
- rel-(2R,4S)-4-(Phosphonomethyl)-2-piperidinecarboxylic acid
- Selfotel
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 3 products.
2-Piperidinecarboxylicacid, 4-(phosphonomethyl)-, (2R,4S)-rel-
CAS:Formula:C7H14NO5PPurity:95%Color and Shape:SolidMolecular weight:223.1635CGS 19755
CAS:<p>CGS 19755 is a low-potency compound that has been investigated for its potential use in the treatment of neurodegenerative diseases. It is a selective, non-competitive antagonist of the metabotropic glutamate receptor type 2 (mGluR2) which has shown to reduce neuronal death and improve motor function in experimental models. CGS 19755 has also been shown to have no significant side-effect profiles in humans and has been tested as a pharmacological agent for the treatment of Parkinson's disease. The major analytical method used to measure the potency of CGS 19755 is intracellular Ca2+ levels.</p>Formula:C7H14NO5PPurity:Min. 95%Molecular weight:223.17 g/mol


